Information Provided By: 
Fly News Breaks for May 3, 2016
MDVN
May 3, 2016 | 08:32 EDT
Credit Suisse analyst Kennen MacKay raised Medivation's (MDVN) price target to $63 from $49 based on a change in valuation methodology to an M&A valuation. The firm continues to view Sanofi's (SNY) $52.50 per share bid as significantly undervaluing Medivation's pipeline and continue to see talazoparib as the potentially best-in-class PARP inhibitor.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
